Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

145.54 +1.95 (+1.36%)
Streaming Delayed Price Updated: 10:15 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
 
Via Benzinga
Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead Drug Candidate
 
Via Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
 
Via Benzinga
Ominous Death Cross Forms On Novo Nordisk's Chart
If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec
 
Via Benzinga
Novo Nordisk's Subcutaneous Semaglutide Shows Positive Action In Type 2 Diabetes
 
Via Benzinga
Novo Nordisk Shares Fall After Q2 Earnings Despite Raised Annual Outlook
 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
 
Via Benzinga
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
The deal helps beef up Novo's early-stage efforts in sickle cell disease. 
Via Investor's Business Daily
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News
There's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news. 
Via InvestorPlace
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
 
Via Benzinga
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
By Paul Henley, Benzinga 
Via News Direct
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... 
Via TheNewswire.com
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. 
Via Benzinga
3 Stocks to Buy Before the Housing Market Crashes
Economists' expectations of a housing market crash are rising, making these potentially stocks stronger choices in the aftermath. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
By Mark Gilman -- Benzinga 
Via News Direct
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via TheNewswire.com
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via Benzinga
3 Top Stocks to Invest In Right Now
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
Weekend Stock Spotlight: Affirm, SoftBank And How Trump Documents Seizure May Impact Midterms
Benzinga reviews this weekend's top stories covered by leading media outlets, here are the articles investors need to read. 
Via Benzinga
The 7 Best Mutual Funds for Your 401k
The best mutual funds for your 401k offer diversification and a margin of safety that can't be found when investing in individual stocks. 
Via InvestorPlace
7 Long-Term Stocks to Buy Before the Bull Market Returns
For massive future returns, consider taking a position in these long-term stocks to buy before the bull market returns. 
Via InvestorPlace
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
 
Via Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
Via Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.